I am a clinician-scientist and urological surgeon with an established track record in translational research. My pioneering work has validated the significance of key signalling pathways, such as the Fibroblast Growth Factor Receptor and the MEK5/ERK5 systems, as prognostic markers and targets for therapy in clinical prostate cancer. This has resulted in large multi-disciplinary academia-industry collaborations in drug discovery programmes.
Through an integrative approach, my research group has been pioneering a number of pre-clinical models for prostate cancer (including transgenic mouse models and metastatic xenograft prostate cancer models), and combined these with state-of-the-art methodologies and resources to study treatment resistant prostate cancer. Based on our recent work on the metabolic trait of castration-resistant prostate cancer, we launched a clinical trial to re-purpose the use of statin as a cholesterol-lowering agent to combat castration-resistant prostate cancer (SPECTRE trial).